0000023313 00000 n and JavaScript.Proton-pump inhibitors (PPIs) induce structural and functional changes in the gastric mucosa related to potent acid suppression, which are exaggerated during The list of adverse events associated with PPI intake is increasing; few of these associations are plausible or proven to have a causal relationshipPPI use can rarely cause acute kidney injury and other morbid conditions related to idiosyncratic effectsLong-term PPI intake interferes with magnesium and calcium homeostasis in small subsets of patients with chronic kidney disease on diuretic therapy; the prevalence of bone fractures attributable to PPIs in older patients is lowThe debate on whether PPIs increase the risk of coronary events in patients on clopidogrel seems to be resolved; the FDA recommends avoiding omeprazole in patients taking clopidogrelProton-pump inhibitors (PPIs) are the most effective therapy for the full spectrum of gastric-acid-related diseases. Lameris, A. L. L., Hess, M. W., van Kruijsbergen, I., Hoenderop, J. G. J. 0000106220 00000 n Ngamruengphong, S., Leontiadis, G., Radhi, S., Dentino, A. Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Studies in primary care and emergency settings suggest that PPIs are frequently prescribed for inappropriate indications or for indications where their use offers little benefit. 1, 2 In many cases, these drugs may be prescribed inappropriately without clear indications and lead to harm (Table (Table1). Stolte, M., Meining, A., Schmitz, J. M., Alexandridis, T. & Seifert, E. Changes in Eissele, R., Brunner, G., Simon, B., Solcia, E. & Arnold, R. Gastric mucosa during treatment with lansoprazole: Sanduleanu, S., Jonkers, D., De Bruïne, A., Hameeteman, W. & Stockbrügger, R. W. Double gastric infection with Schulz, C., Koch, N., Schütte, K., Pieper, D. H. & Malfertheiner, P. H. pylori and its modulation of gastrointestinal microbiota. Yang, Y. X., Lewis, J. D., Epstein, S. & Metz, D. C. Long-term proton pump inhibitor therapy and risk of hip fracture. Thank you for visiting nature.com. Giamarellos-Bourboulis, E. J., Pyleris, E., Barbatzas, C., Pistiki, A.

Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology. By continuing to browse this site, you agree to its use of cookies as described in our I have read and accept the Wiley Online Library Terms and Conditions of UseProton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosisUse and overuse of proton pump inhibitors in cirrhotic patientsUse of proton pump inhibitors in the management of gastroesophageal varices: a systematic reviewPPIs are not associated with a lower incidence of portal‐hypertension‐related bleeding in cirrhosisAcid‐suppressive therapy is associated with spontaneous bacterial peritonitis in cirrhotic patients: a meta‐analysisSystematic review and meta‐analysis of the possible association between pharmacological gastric acid suppression and spontaneous bacterial peritonitisProton pump inhibitor use and risk of spontaneous bacterial peritonitis in cirrhotic patients: a systematic review and meta‐analysisProton pump inhibitor therapy and its association with spontaneous bacterial peritonitis incidence and mortality: a meta‐analysisProton pump inhibitor therapy does not increase the incidence of spontaneous bacterial peritonitis in cirrhosis: a multicenter prospective studyProton pump inhibitors as a risk factor for hepatic encephalopathy and spontaneous bacterial peritonitis in patients with cirrhosis with ascitesProton pump inhibitors increase risk for hepatic encephalopathy in patients with cirrhosis in a population studyProton pump inhibitors alter the composition of the gut microbiotaAlterations of the human gut microbiome in liver cirrhosisIs intestinal inflammation linking dysbiosis to gut barrier dysfunction during liver disease?Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta‐analysisUse of proton pump inhibitors decrease cellular oxidative burst in patients with decompensated cirrhosisAssociation of proton pump inhibitor therapy with spontaneous bacterial peritonitis in cirrhotic patients with ascitesIncreased rate of spontaneous bacterial peritonitis among cirrhotic patients receiving pharmacologic acid suppressionRole of proton pump inhibitors in the occurrence and the prognosis of spontaneous bacterial peritonitis in cirrhotic patients with ascitesAssociation between proton pump inhibitor use and spontaneous bacterial peritonitis in cirrhotic patients with ascitesProton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascitesThe impact of proton pump inhibitor therapy on patients with liver diseaseClinical Significance of Changes in the Gut Microbiome Associated with the Use of Proton Pump Inhibitors, The Korean Journal of Helicobacter and Upper Gastrointestinal Research, Proton pump inhibitors in chronic liver disease: accomplice or bystander?, Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis, Chronic PPI use could cause hepatic encephalopathy in patients with cirrhosis,